ANI Pharma (ANIP) Launches Nitazoxanide Tablets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
March 19, 2025 6:50 AM EDTPRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANIs Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®.
"The market launch of Nitazoxanide Tablets, another niche limited competition product, underscores our purpose of Serving Patients, Improving Lives, stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
"We share ANIs commitment to providing affordable, high-quality medicines for the patients who depend on them and are... More



